Enhanced Telehealth Delivery of Cancer Care at Home to Improve Care for Patients with Breast or Prostate Cancer, The MATCH-UP Trial

PRIMARY OBJECTIVE:

I. To compare the enhanced telehealth practice pattern (ET) to usual practice patterns (UPP) over the course of 12 months in terms of the proportion of face-to-face routine visits out of total medical oncology related visits for patients with breast and prostate cancer.

SECONDARY OBJECTIVES:

I. To assess the safety and effectiveness of ET regarding healthcare utilization as compared to UPP.

II. To assess patient quality of life on ET arm as compared to UPP.

III. To compare ET and UPP regarding indirect healthcare costs and time spent by patients and their caregivers.

IV. To compare ET and UPP with respect to patient visit experience and visit type preferences.

V. To compare ET and UPP with respect to clinician visit experience and visit type preferences.

VI. To assess telehealth accessibility for patients in the ET arm. (ET arm only)

VII. To assess the efficiency of the ancillary at home components of the complex ET intervention. (ET arm only)

VIII. To assess clinician and patient perspectives on the implementation of the ET complex intervention. (ET arm only).

EXPLORATORY OBJECTIVE:

I. To assess telehealth barriers for all patients and describe implementation outcomes of Making Telehealth Delivery of Cancer Care at Home (MATCH-Line) digital support pilot program for ET arm patients.

OUTLINE: Medical oncology physician practices are randomized to 1 of 2 arms. Patients are assigned to 1 of 2 arms based on their physician location.

ARM I: Patients receive routine care according to the usual practice for 12 months.

ARM II: Patients receive oncology follow up visits via telehealth and phlebotomy visits at home, unless patient or care team request the visit be in-person, for 12 months. Patients also receive home lab visits from mobile phlebotomy services, as well as referral to the MATCH-Line program for 12 months that includes digital tools, education, and/or referrals to additional existing resources at Memorial Sloan Kettering (MSK) based upon individual needs. In addition, patients receiving subcutaneous (SC) or intramuscular (IM) injections amenable to self-injection receive education to support patients and their caregivers to administer at home for 12 months.